Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.

Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC.

Pain. 2018 May;159(5):987-994. doi: 10.1097/j.pain.0000000000001174.


Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, Sawada T, Nagata TD.

Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176. doi: 10.1093/ofid/ofx176. eCollection 2017 Summer.


Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers.

Fukumura K, Yokota T, Baba Y, Arjona Ferreira JC.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):474-483. doi: 10.1002/cpdd.387. Epub 2017 Sep 27.


Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.

Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564. doi: 10.1016/S2468-1253(17)30105-X. Epub 2017 May 30.


Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.

Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C.

J Clin Pharmacol. 2017 May;57(5):584-591. doi: 10.1002/jcph.841. Epub 2016 Nov 22.


Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.

Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01381-16. doi: 10.1128/AAC.01381-16. Print 2017 Jan.


Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.

Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ.

Diabetes Obes Metab. 2015 Nov;17(11):1033-41. doi: 10.1111/dom.12507. Epub 2015 Jul 17.


Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes.

Tajima N, Kadowaki T, Okamoto T, Sato A, Okuyama K, Minamide T, Arjona Ferreira JC.

J Diabetes Investig. 2013 Nov 27;4(6):595-604. doi: 10.1111/jdi.12116. Epub 2013 Jul 21.


Primary objective of study of sitagliptin in patients with ESRD on dialysis.

Arjona Ferreira JC, Golm GT, Goldstein BJ.

Am J Kidney Dis. 2013 Sep;62(3):642. doi: 10.1053/j.ajkd.2013.05.026. No abstract available.


Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.

Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, Golm GT, Gonzalez EJ, Davies MJ, Kaufman KD, Goldstein BJ.

Am J Kidney Dis. 2013 Apr;61(4):579-87. doi: 10.1053/j.ajkd.2012.11.043. Epub 2013 Jan 24. Erratum in: Am J Kidney Dis. 2013 Oct;62(4):847.


Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.

Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ.

Diabetes Care. 2013 May;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17.


Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.

Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM.

Diabetes Obes Metab. 2010 Jul;12(7):613-22. doi: 10.1111/j.1463-1326.2010.01197.x.


Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J.

Endocr J. 2010;57(5):383-94. Epub 2010 Mar 24.


Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.

Kanazu S, Horie Y, Narukawa M, Nonaka K, Taniguchi T, Arjona Ferreira JC, Takeuchi M.

Diabetes Obes Metab. 2009 Aug;11(8):813-8. doi: 10.1111/j.1463-1326.2009.01058.x. Epub 2009 May 19.


Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D.

Diabetes Obes Metab. 2008 Jul;10(7):545-55. doi: 10.1111/j.1463-1326.2008.00914.x. Epub 2008 Jun 1.


Supplemental Content

Loading ...
Support Center